United Kingdom Drug Delivery Devices Market Size & Share Analysis - Growth Trends And Forecast (2026 - 2031)

The United Kingdom drug delivery devices market size is expected to grow from USD 8.92 billion in 2025 to USD 9.58 billion in 2026 and is forecast to reach USD 13.65 billion by 2031 at 7.36% CAGR over 2026-2031. Growth is propelled by the National Health Service (NHS) drive for precision medicine, rising adoption of home-based care, and accelerated approval pathways that shorten time-to-market for innovative devices. Every 1% gain in adherence is estimated to save the NHS about GBP 500 million in avoided hospital admissions, keeping cost reduction at the center of procurement strategies.^{[1]NHS England, “Medicines Value Programme,” england.nhs.uk} Post-Brexit regulation has shifted to UKCA marking, yet the new International Reliance procedure allows devices cleared in Australia, Canada, the European Union, or the United States to enter the United Kingdom drug delivery devices market more rapidly, sustaining the country’s attractiveness for foreign innovators. Sustainability also matters: near-zero global-warming-potential (GWP) propellants in next-generation pressurised metered-dose inhalers (pMDIs) are helping manufacturers win NHS tenders while meeting carbon-reduction targets. A parallel surge in connected devices responds to medication non-adherence that costs the NHS roughly GBP 637 million each year.^{[2]National Institute for Health and Care Research, “Impact of Non-Adherence on Healthcare Outcomes,” nihr.ac.uk}

An extra GBP 86 million added to the Disabled Facilities Grant in 2025 enables more patients to manage conditions at home, complementing the Pharmacy First scheme that now covers seven minor conditions at almost every community pharmacy.^{[3]Department of Health and Social Care, “NHS Long Term Plan 2024-2034,” gov.uk} The NHS plan to distribute artificial-pancreas technology over five years exemplifies policy-driven demand for intuitive self-use systems. Such measures channel volume into the United Kingdom drug delivery devices market for pen injectors, wearable pumps, and inhalers designed for layperson operation.

Connected devices are expected to post a doubt digit CAGR in United Kingdom healthcare through 2030 as electronic health-record coverage climbs toward 95% of NHS trusts. Smart inhalers reimbursed under the MedTech Funding Mandate and Bluetooth add-ons like DOSE for insulin pens show how IoT integration addresses non-adherence that leads to 22,000 premature deaths a year. The broad data backbone being built by the Digital Health and Care Plan lets these devices feed real-time dosing data directly into clinical workflows.

Conference agendas and product pipelines confirm high-volume injectable formats as a priority for biologic and biosimilar launches. GSK’s specialty-medicine sales rose 22% in Q2 2024, much of it tied to oncology and HIV therapies that require sophisticated delivery systems. With 85 biologic patents due to expire by 2028, biosimilar competition is intensifying the need for cost-efficient yet user-friendly autoinjectors within the United Kingdom drug delivery devices market.

A GBP 400 million package for clinical-trial acceleration and a dedicated Intracellular Drug Delivery Centre focused on lipid nanoparticle research highlight the government’s long-term commitment to platform breakthroughs.^{[4]Association of the British Pharmaceutical Industry, “UK Secures £400 Million Investment,” abpi.org.uk} Grants for technologies such as DriDose nasal powders illustrate targeted support for innovators outside big-pharma circles, broadening the innovation base.

Manufacturers must maintain both CE and UKCA certification until 2030, and the post-market-surveillance rules effective June 2025 widen the definition of a serious incident. Non-UK suppliers must appoint a Responsible Person, adding cost and complexity, although expansion of approved bodies and an International Reliance route offer partial relief.

Software-heavy connected devices raise spending beyond traditional hardware budgets, and the United Kingdom lacks abundant GMP-grade clean-room capacity. The NHS spends GBP 3.8 billion a year on aseptically produced injectables, prompting proposals for regional hub facilities to ease bottlenecks. Targeted grants, such as GBP 33 million for greener inhaler production, help but do not fully offset the capital burden for smaller firms.